Meta-analysis of the prognostic value of lncRNA ZFAS1 in patients with solid tumors

Wei Song; Chuan Tian; Run-Jin Zhang; Shu-Bing Zou; Kai Wang

doi:10.18632/oncotarget.19566

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Meta-Analysis:

Meta-analysis of the prognostic value of lncRNA ZFAS1 in patients with solid tumors

Wei Song, Chuan Tian, Run-Jin Zhang, Shu-Bing Zou _ and Kai Wang

PDF | HTML | How to cite

Oncotarget. 2017; 8:90301-90307. https://doi.org/10.18632/oncotarget.19566

Metrics: PDF 1387 views | HTML 2330 views | ?

Abstract

Wei Song1,*, Chuan Tian2,*, Run-Jin Zhang1, Shu-Bing Zou1 and Kai Wang1

1Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China

2Department of Nuclear Medicine, Guizhou Provincial People’s Hospital, Guiyang, China

*These authors contributed equally to this work

Correspondence to:

Shu-Bing Zou, email: [email protected]

Kai Wang, email: [email protected]

Keywords: ZFAS1, long noncoding RNA, cancer, prognosis, meta-analysis

Received: March 22, 2017 Accepted: July 18, 2017 Published: July 26, 2017

ABSTRACT

Expression of ZFAS1, a newly identified long noncoding RNA (lncRNA), is dysregulated in several types of cancer. Here we assessed the prognostic value of ZFAS1 in solid tumors. A comprehensive literature search was performed by screening the PubMed, EMBASE, MEDLINE, Cochrane Library, CNKI, and Wanfang databases. A total of 874 patients from 10 studies were included. The pooled analysis demonstrated that patients with high ZFAS1 expression had a significantly shorter overall survival (OS) (HR, 1.58; 95% CI, 1.28–1.97; P < 0.001) and recurrence-free survival (RFS) (HR, 1.90; 95% CI, 1.29–2.79; P = 0.001). Moreover, elevated ZFAS1 expression correlated with tumor size, tumor-node-metastasis (TNM) stage, and lymph node metastasis (LNM). These results demonstrate that increased ZFAS1 expression correlates with a poor prognosis in cancer patients, which suggests ZFAS1 might be useful as a potential prognostic biomarker in patients with solid tumors.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19566

Publication Alerts

Post-Publication Promotion

Publication Discount

Meta-Analysis:

Meta-analysis of the prognostic value of lncRNA ZFAS1 in patients with solid tumors

Abstract